Alzheimer s Disease Pilot Clinical Trials (R01)

The summary for the Alzheimer s Disease Pilot Clinical Trials (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Alzheimer s Disease Pilot Clinical Trials (R01): n 1999, at the direction of Congress, the National Institute on Aging (NIA), in conjunction with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) embarked on the Alzheimer's Disease (AD) Prevention Initiative, which encompasses a number of interrelated efforts including basic, epidemiological, behavioral, and clinical research. An important part of the AD Prevention Initiative is to quicken the pace for translating basic science findings into clinical trials to evaluate treatment and prevention strategies. This funding opportunity announcement (FOA) focuses on AD pilot clinical trials while another FOA is targeted to AD drug discovery. In this FOA the NIA invites qualified investigators to submit research grant applications for pilot clinical drug trials directed toward the prevention and treatment of the cognitive and behavioral symptoms of mild cognitive impairment (MCI), Alzheimer's disease (AD), and age-related cognitive decline. This Funding Opportunity Announcement (FOA) issued by the National Institute on Aging (NIA), National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/ organizations that propose to initiate pilot clinical trials for treatment or prevention of MCI, AD, and/or age related cognitive decline. Purpose. The objective of the Alzheimer s Disease Pilot Clinical Trials initiative is to improve the quality of clinical research designed to evaluate interventions for the prevention or treatment of Alzheimer s disease (AD), mild cognitive impairment (MCI), and age-associated cognitive decline by stimulating applications for pilot clinical drug trials to test interventions aimed at delaying the onset of or preventing AD, MCI, and age-associated cognitive decline; slowing, halting, or, if possible, reversing the progressive decline in cognitive function; and modifying the cognitive and behavioral symptoms in Alzheimer s disease. Mechanism of Support. This FOA will utilize the R01 grant mechanism. Funds Available and Anticipated Number of Awards. It is expected that most grants will not exceed $400,000 per year in direct costs (exclusive of indirect costs for subcontracts to additional clinical sites) for up to 3 years. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the numbers, quality, duration, and costs of the applications received.